Literature DB >> 6414692

Clinical overview of mesna.

H Burkert.   

Abstract

Mesna is superior to standard prophylaxis in inhibiting the urotoxicity of oxazaphosphorines. Mesna does not interfere with the antitumour effect of oxazaphosphorines and other cytostatics. Mesna is well tolerated. Mesna can be given orally. Mesna should be administered with each ifosfamide treatment and with high dose cyclophosphamide. It should also be given to any patient who may be at risk of developing cystitis following oxazaphosphorine treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6414692     DOI: 10.1016/s0305-7372(83)80026-7

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  13 in total

Review 1.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

2.  Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.

Authors:  C A James; T G Mant; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

3.  Analysis of sodium 2-mercaptoethane sulfonate in rat plasma using high performance liquid chromatography tandem-mass spectrometry.

Authors:  Abigail B Donkor; Carl W White; Heidi J Nick; Brian A Logue
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2021-12-22       Impact factor: 3.205

4.  A phase II study of ifosfamide in children with recurrent solid tumours.

Authors:  C R Pinkerton; H Rogers; C James; A Bowman; P R Barbor; O B Eden; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.

Authors:  M Fukuoka; S Negoro; N Masuda; K Furuse; M Kawahara; N Kodama; H Ikegami; S Nakamura; H Nishio; T Ohnoshi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.

Authors:  S A Al-Safi; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

7.  Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols.

Authors:  N Brock; P Hilgard; J Pohl; K Ormstad; S Orrenius
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

8.  A phase II study of ifosfamide in paediatric solid tumours.

Authors:  C R Pinkerton; J Pritchard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 9.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

10.  Severe renal failure following high-dose ifosfamide and mesna.

Authors:  P H Willemse; P E de Jong; J D Elema; N H Mulder
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.